- Home
- NMTC vs INAB Comparison
NMTC vs INAB Comparison
Compare NMTC & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMTC
- INAB
- Stock Information
- Founded
- NMTC 2009
- INAB 2016
- Country
- NMTC United States
- INAB United States
- Employees
- NMTC N/A
- INAB N/A
- Industry
- NMTC Medical/Dental Instruments
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- NMTC Health Care
- INAB Health Care
- Exchange
- NMTC Nasdaq
- INAB Nasdaq
- Market Cap
- NMTC 21.0M
- INAB 18.8M
- IPO Year
- NMTC N/A
- INAB 2021
- Fundamental
- Price
- NMTC $0.91
- INAB $0.25
- Analyst Decision
- NMTC
- INAB Strong Buy
- Analyst Count
- NMTC 0
- INAB 3
- Target Price
- NMTC N/A
- INAB $5.57
- AVG Volume (30 Days)
- NMTC 209.4K
- INAB 14.9M
- Earning Date
- NMTC 02-12-2025
- INAB 03-17-2025
- Dividend Yield
- NMTC N/A
- INAB N/A
- EPS Growth
- NMTC N/A
- INAB N/A
- EPS
- NMTC N/A
- INAB N/A
- Revenue
- NMTC $5,749,521.00
- INAB N/A
- Revenue This Year
- NMTC $292.88
- INAB N/A
- Revenue Next Year
- NMTC N/A
- INAB N/A
- P/E Ratio
- NMTC N/A
- INAB N/A
- Revenue Growth
- NMTC 104.21
- INAB N/A
- 52 Week Low
- NMTC $0.55
- INAB $0.22
- 52 Week High
- NMTC $1.50
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- NMTC 33.57
- INAB 42.97
- Support Level
- NMTC $1.01
- INAB $0.24
- Resistance Level
- NMTC $1.16
- INAB $0.28
- Average True Range (ATR)
- NMTC 0.09
- INAB 0.03
- MACD
- NMTC -0.03
- INAB -0.00
- Stochastic Oscillator
- NMTC 13.64
- INAB 20.74
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.